Oral sessions summaries
AMR Gonorrhea
View
The threat of antimicrobial resistant gonorrhea
Expert commentary by Nuno Gomes, MD
EADV Virtual - Oral session
Alopecia Areata
View
Initial results from a long-term, open-label extension study with CTP-543, an oral janus kinase inhibitor, in patients with moderate to severe alopecia areata
Expert Commentary by Prof. Bianca Maria Piraccini, MD, PhD
EADV Virtual - Oral session
Alopecia Areata
View
Emerging therapies for alopecia areata
Expert commentary by Anna Waśkiel-Burnat, MD, PhD
EADV Virtual - Oral session
Atopic Dermatitis
View
Safety and Efficacy of Upadacitinib Monotherapy in Adolescents and Adults with Moderate-to-severe Atopic Dermatitis: Results From 2 Pivotal, Phase 3, Randomized, Double-blinded, Monotherapy, Placebo-controlled Studies (Measure Up 1 and Measure Up 2)
EADV Virtual - Oral session
COVID-19
View
Management of COVID-19: The dermatologist’s perspective
Expert commentary by Mihaela Leventer, MD
EADV Virtual - Oral session
COVID-19
View
Use of biologics and immunosuppressive drugs in COVID period
EADV Virtual - Oral session
Chronic Hand Eczema
View
A phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of gusacitinib (ASN002) in subjects with moderate-to-severe chronic hand eczema
Expert commentary by Peter Lio, MD
EADV Virtual - Oral session
Epidermolysis Bullosa
View
Efficacy and safety of oleogel-S10 for epidermolysis bullosa – Results of 3 months double-blind treatment during the phase 3 study EASE
Expert commentary by Carolina Gouveia, MD
EADV Virtual - Oral session
Hidradenitis Suppurativa
View
Biologics in the management of hidradenitis suppurativa
EADV Virtual - Oral session
Metastatic Melanoma
View
Immunotherapy in metastatic melanoma
Expert commantary by Caroline Robert, MD, PhD
EADV Virtual - Oral session
Scars
View
Future of medical scar treatment
Expert commentary by Severin Laeuchli, MD
EADV Virtual - Oral session
-
DOWNLOAD
THE APP